Skip to main content

Table 2 Compliance with QOL assessment

From: Quality-of-life evaluation for advanced non-small-cell lung cancer: a comparison between vinorelbine plus gemcitabine followed by docetaxel versus paclitaxel plus carboplatin regimens in a randomized trial: Japan Multinational Trial Organization LC00-03 (BRI LC03-01)

 

PC group (n = 34)

VGD group (n = 34)

Assessment time

Baseline

6 week

12 week

18 week

Baseline

6 week

12 week

18 week

No. of evaluable patients

34

34

23

13

34

34

24

20

Discontinuation of protocol treatment

0

0

11

10

0

0

10

4

Investigator's error

0

1

1

1

0

1

0

1

No reason provided

0

0

0

0

0

0

1

1

No. of submitted questionnaires

Compliance (%)

34

100%

33

97%

22

96%

12

92%

34

100%

33

97%

23

96%

18

90%